MedTrace Logo

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

NCT01498952 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-02-19

Study results available
· View outcomes & findings →

Summary

A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).

Conditions

  • Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

Interventions

DRUG

MEDI-573 (1 of 3 doses)

MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands

DRUG

Sorafenib

Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Susan Perez, MD · MedImmune LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-17
Primary Completion
2013-04-09
Completion
2013-04-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01498952 on ClinicalTrials.gov